SURINPARK: Safinamide for Urinary Symptoms in Parkinson’s Disease
Background: Urinary symptoms are common, disabling and generally unresponsive to treatment in Parkinson´s disease (PD). Safinamide is approved as an add-on therapy to levodopa to improve fluctuations. Methods: Retrospective analysis of electronic records of nondemented PD patients seen consecutively...
Main Authors: | Ana Gómez-López, Arantxa Sánchez-Sánchez, Elena Natera-Villalba, Victoria Ros-Castelló, Álvaro Beltrán-Corbellini, Samira Fanjul-Arbós, Isabel Pareés Moreno, José Luis López-Sendon Moreno, Juan Carlos Martínez Castrillo, Araceli Alonso-Canovas |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-01-01
|
Series: | Brain Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-3425/11/1/57 |
Similar Items
-
The Current Evidence for the Use of Safinamide for the Treatment of Parkinson’s Disease
by: Abbruzzese G, et al.
Published: (2021-06-01) -
A Spanish Consensus on the Use of Safinamide for Parkinson’s Disease in Clinical Practice
by: Javier Pagonabarraga, et al.
Published: (2020-03-01) -
Safinamide in the management of patients with Parkinson’s disease not stabilized on levodopa: a review of the current clinical evidence
by: Bette S, et al.
Published: (2018-09-01) -
Adjuvant therapies for Parkinson’s disease: critical evaluation of safinamide
by: Stocchi F, et al.
Published: (2016-02-01) -
Impact of SAfinamide on Depressive Symptoms in Parkinson’s Disease Patients (SADness-PD Study): A Multicenter Retrospective Study
by: Esteban Peña, et al.
Published: (2021-02-01)